Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure

European Journal of Heart Failure

Volumn 2, Issue 1, 2000, Pages 81-90

  Pietilä, Mikko ^a   Malminiemi, Kimmo ^b   Huupponen, Risto ^c   Rouru, Juha ^c   Pulkki, Kari ^a   Pere, Erkki ^d   Voipio Pulkki, Liisa Maria ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Celiprolol; Clinical trial; Euglycaemic clamp; Exercise training; Heart failure; Insulin sensitivity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; CHOLESTEROL DERIVATIVE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; OXYGEN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; FEMALE; HEART FAILURE; HUMAN; INSULIN SENSITIVITY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAINING; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CELIPROLOL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EXERCISE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 0034037018     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00054-4     Document Type: Article

References (34)

1. Swan J.W., Walton C., Godsland I.F., Clark A.L., Coats A.J.S., Oliver M.F. Insulin resistance in chronic heart failure. Eur Heart J. 15:1994;1528-1532.
2. Devlin J.T. Effects of exercise on insulin sensitivity in humans. Diabetes Care. 15(suppl.4):1992;1690-1693.
3. Koivisto V.A., Yki-Järvinen H., DeFronzo D.A. Physical training and insulin sensitivity. Diabetes Metab Rev. 1:1986;445-481.
4. Malminiemi K., Lahtela J.T., Huupponen R. Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. Int J Clin Pharmacol Ther. 33(3):1995;156-163.
5. Dunn C.J., Spencer C.M. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging. 7:1995;394-411.
6. Alaranta H., Hurri H., Heliovaara M., Soukka A., Harju R. Non-dynamometric trunk performance tests: reliability and normative data. Scand J Rehabil Med. 26(4):1994;211-215.
7. DeFronzo R.A., Tobin J.A., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237:1979;E214-E223.
8. Siedel J., Schlumberger H., Klose S., Ziegenhorn J., Wahlefeld A.W. Improved reagent for the enzymatic determination of serum cholesterol. J Clin Chem Clin Biochem. 19:1981;838-839.
9. Wahlefeld A.W. Triglycerides - determination after enzymatic hydrolysis. Bergmeyer H.V. Methods of enzymatic analysis. 2nd ed. 1974;1831-1835 Verlag Chemie/Academic Press, New York.
10. Izzo C., Grillo F., Murador E. Improved method for determination of high-density-lipoproteins by use of polyethylene glycol 6000. Clin Chem. 27:1981;371-374.
11. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18(6):1972;499-502.
12. Wellstein A., Palm D., Pitchner H.F., Belz G.G. Receptor-binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol. 29:1985;131-147.
13. Coats A.J.S., Adamopoulos S., Mayer T.E., Conway J., Sleight P. Effects of physical training in chronic heart failure. Lancet. 335:1990;63-66.
14. Coats A.J.S., Clark A.L., Piepoli M., Volterrani M., Poole-Wilson P.A. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 72:1994;S36-39.
15. Tyni-Lenne R., Gordon A., Sylven C. Improved health-related quality of life in moderate chronic heart failure following submaximal exercising of leg muscle. J Card Failure. 2:1996;111-117.
16. Doughty R.N., Sharpe N., MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J. 18:1997;560-565.
17. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 349:1997;375-380.
18. Demopoulos L., Yeh M., Gentilucci M. et al. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation. 95(7):1997;1764-1767.
19. Lind L., Pollare T., Berne C., Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J. 128:1994;1177-1183.
20. Swan J.W., Walton C., Godsland I.F., Clark A.L. Relationship of insulin resistance to the severity and etiology of chronic heart failure. Circulation. 90:1994;I-74.
21. Swan J.W., Anker S.D., Walton C. et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 30(2):1997;527-532.
22. Paternostro G., Camici P., Lammertsma A. et al. Cardiac and skeletal muscle insulin resistance in patients with coronary artery disease. J Clin Invest. 9:1996;2094-2099.
23. Amato L., Paolisso G., Cacciatore F. et al. Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes-Metab. 23(3):1997;213-218.
24. Anker S.D., Leyva F., Poole-Wilson P.A., Kox W.J., Stevenson J.C., Coats A.J. Relation between serum uric acid concentration and lower limb blood flow in patients with chronic heart failure. Heart. 78(1):1997;39-43.
25. Houghton A.R., Harrison M., Perry A.J., Evans A.J., Cowley A.J. Endogenous insulin and insulin sensitivity. Eur Heart J. 19:1998;476-480.
26. Yki-Järvinen H., Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia. 41:1998;369-379.
27. 18F] fluoro-deoxy-glucose and positron emission tomography. J Clin Invest. 97:1996;1741-1747.
28. Katz S.D., Yuen J., Bijou R., Le Jemtel T.H. Training improves endothelium-dependent vasodilatation in resistance vessels of patients with heart failure. J Appl Physiol. 82(5):1997;1488-1492.
29. Hambrecht R, Fiehn E, Jiangtao Y et al. Altered peripheral perfusion and skeletal muscle metabolic response to exercise in patients with chronic heart failure: chronic effect of endurance training. Circulation 1996;96(8) suppl.1:I 192 (Abstract).
30. Ohtsubo M., Yonezawa K., Nishijima H. et al. Metabolic abnormality of calf skeletal muscle is improved by localized muscle training without changes in blood flow in chronic heart failure. Heart. 78(5):1997;437-443.
31. Tung L.H., Jackman G., Cambpell B., Louis S., Iakovidis D., Louis W.J. Partial agonist activity of celiprolol. J Cardiovasc Pharmacol. 21:1993;484-488.
32. Dhein S., Titzer S., Wallstein M. et al. Celiprolol exerts microvascular dilatation by activation of beta-2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 346:1992;27-31.
33. 18F- fluorodeoxyglucose and positron emission tomography. Eur J Clin Pharmacol. 52(1):1997;19-26.
34. Lavie C.J., Milani R.V. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol. 79(4):1997;397-401.